echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Eli Lilly, Amgen, Pfizer and many pharmaceutical giants have sprinted to the "weight loss" market

    Eli Lilly, Amgen, Pfizer and many pharmaceutical giants have sprinted to the "weight loss" market

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    It is expected to reach $50 billion in revenue in ten years! A war against obesity is being waged
    in the global pharmaceutical community.
    It is reported that pharmaceutical companies such as Eli Lilly, Amgen, Pfizer, and Regeneron have targeted this broad track
    .

     
    For example, Eli Lilly has announced that the FDA has granted fast-track qualification for Tirzepatide (telpotide) injection for the treatment of obesity indications to accelerate the approval
    of this indication.
    As a GLP-1R/GIP dual-target hypoglycemic drug for the treatment of type 2 diabetes, this drug has attracted a lot of attention
    in the experimental stage.

     
    It is reported that according to the results of the phase 3 clinical trial SURPASS-2 published by Lilly, compared with Novo Nordisk 1 mg injectable semeglutide, three doses of Tirzepatide can significantly reduce
    glycated hemoglobin and body weight from baseline in adult patients with type 2 diabetes.

     
    The highest dose of Tirzepatide (15 mg) reduced glycosylated hemoglobin (A1C) by 2.
    46% and body weight by 12.
    4 kg (13.
    1%); The lowest dose of Tirzepatide (5 mg) reduced A1C by 2.
    09% and body weight by 7.
    8 kg (8.
    5%), compared with semeglutide by 1.
    86% and 6.
    2 kg (6.
    7%)
    , respectively.

     
    In addition, according to the approval schedule, Mounjaro, a diabetes drug owned by Eli Lilly that has both hypoglycemic and weight reduction, is also expected to obtain indications
    for the treatment of overweight next year.

     
    On December 1, Amgen also announced the data
    of its new phase 1 clinical trial of obesity therapy AMG 133.
    According to public information, AMG 133 is a potential "first-in-class" antibody peptide conjugated drug, which is administered once a
    month.
    The results of the Phase 1 clinical trial showed that subjects lost 14.
    5%
    of their body weight after 12 weeks of treatment with the highest dose of AMG 133.

     
    Amgen said AMG133 was designed based on preclinical and human genetic data, which suggest that GIPR inhibition is a weight loss strategy, especially when
    combined with GLP-1 agonists.
    "We look forward to launching the second phase of the study
    early next year.
    "
     
    It is reported that Pfizer has also set its sights on this tens of billions of dollars market
    .
    In mid-December, the company announced that it would advance late-stage trials
    of its oral GLP-1 drug.
    At the investor conference, Pfizer envisioned the drug's potential
    to reach $10 billion in annual sales by 2030.
    From the perspective of the mode of administration, compared with injectable drugs, the affinity of oral drugs for patients is obviously much
    better.

     
    According to the data, glucagon-like peptide 1 (GLP-1) is a peptide hormone secreted by intestinal cells, which stimulates the secretion of insulin by binding to GLP-1 receptors and inhibits the secretion of glucagon, thereby promoting glucose metabolism
    .
    At the same time, it can also delay gastric emptying and suppress appetite
    .
    Therefore, it is a powerful target for the treatment of obesity and type 2 diabetes
    .

     
    In addition, Regeneron Pharmaceuticals is looking for breakthroughs from the perspective of gene therapy, the company found that a gene called GPR75 can reduce the probability of obesity in the population by 60%, and is currently working with multiple partners to develop different drug forms
    .

     
    Obesity is a chronic disease that requires long-term management
    .
    It is associated with
    many serious health consequences and reduced life expectancy.
    There are many obesity-related complications, including type 2 diabetes, heart disease, obstructive sleep apnea, nonalcoholic fatty liver disease, and cancer
    .
    At present, obesity has become one of the important factors affecting the health of residents, so it is urgent
    to strengthen the research and development of related drugs.

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.